About the Event
Hear from Jeff Casberg and Julie Kendle of IPD Analytics, as they share:
- The status of launched biosimilars and anticipated developments in the biosimilar pipeline for 2024 and beyond.
- Management strategies for unbranded biosimilars and PBM formulary exclusion lists.
- How commercial employers and payers will be impacted by the prescription drug pricing provisions in the Inflation Reduction Act.
This presentation was previously recorded at the 2024 Annual Benefits Forum on March 6, 2024.